newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference

  • Chemomab Therapeutics CEO Dr. Adi Mor will present at the H.C. Wainwright 28th Annual Global Investment Conference.
  • The prerecorded webcast presentation is available starting September 11, 2026, at 7:00 am ET for 90 days.
  • Dr. Mor & Scipher Medicine CEO Dr. Reg Seeto will co-host 1x1 investor meetings in New York City from September 14-16, 2026.
  • Chemomab & Scipher announced a definitive merger agreement on July 8, 2026, expected to close before year-end 2026.
  • Scipher plans to advance Chemomab's anti-CCL24 antibody nebokitug into a Phase 2 trial for rheumatoid arthritis.
  • Nebokitug is a first-in-class dual activity monoclonal antibody neutralizing CCL24 with favorable safety profiles in five clinical trials.
  • The rheumatoid arthritis market represents a $24 billion opportunity with substantial unmet need.
  • Chemomab is a clinical-stage biotechnology company developing therapeutics for immune-fibrotic diseases.
  • Scipher utilizes AI, network biology, & proprietary data platforms like SPECTRA to advance drug development probability.
  • Scipher markets PrismRA, a precision medicine blood test for rheumatoid arthritis affecting over 20 million patients globally.
  • Chemomab has filed a draft Form S-4 with the SEC regarding the proposed merger & intends to publicly file the registration statement.
  • Forward-looking statements in the press release include risks regarding merger completion, clinical trial timelines, & regulatory approvals.